Vitamin D and Hepatitis C Virus-relatedLiver Disease
Abudeif, A., Galal, G., Mohammad, A., Agamy, M., Ahmad, N., Fahmy, N. (2019). Vitamin D and Hepatitis C Virus-relatedLiver Disease. EKB Journal Management System, 23(Issue 1), 31-38. doi: 10.21608/smj.2019.40893
Ahmed Abudeif; Ghada Moustafa Galal; Asmaa Naser Mohammad; Maha Mohamed Agamy; Nagwa Sayed Ahmad; Nahed Fathallah Fahmy. "Vitamin D and Hepatitis C Virus-relatedLiver Disease". EKB Journal Management System, 23, Issue 1, 2019, 31-38. doi: 10.21608/smj.2019.40893
Abudeif, A., Galal, G., Mohammad, A., Agamy, M., Ahmad, N., Fahmy, N. (2019). 'Vitamin D and Hepatitis C Virus-relatedLiver Disease', EKB Journal Management System, 23(Issue 1), pp. 31-38. doi: 10.21608/smj.2019.40893
Abudeif, A., Galal, G., Mohammad, A., Agamy, M., Ahmad, N., Fahmy, N. Vitamin D and Hepatitis C Virus-relatedLiver Disease. EKB Journal Management System, 2019; 23(Issue 1): 31-38. doi: 10.21608/smj.2019.40893

Vitamin D and Hepatitis C Virus-relatedLiver Disease

Sohag Medical Journal
Article 12, Volume 23, Issue 1, January 2019, Page 31-38  XML PDF (449.4 K)
Document Type: Original Article
DOI: 10.21608/smj.2019.40893
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Abudeiforcid 1; Ghada Moustafa Galal1; Asmaa Naser Mohammad1; Maha Mohamed Agamy1; Nagwa Sayed Ahmad2; Nahed Fathallah Fahmy3
1Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Sohag University.
2Debartment of Biochemistry, Faculty of Medicine, Sohag University.
3Department of Medical Microbiology and Immunology,Faculty of Medicine, Sohag University.
Abstract
Vitamin D through the vitamin D receptor (VDR) is involved in the control of bone and calcium homeostasis, immunoregulation, cellular differentiation,and anti-inflammatoryactions.The liver is central in vitamin D synthesis, however the direct involvement ofthe vitamin D with chronic liver disease, chronic hepatitis C (CHC) infection, and hepatocellular carcinoma (HCC) remains to be evaluated.The purpose of thisreview is to describevitamin D metabolism, the mechanisms of homeostatic control, and to address the associationsbetween vitamin D and HCV-related liver disease.
Supplementary Files
References
  1. Combs GF, McClung JP. Vitamin D. In: Combs GF, McClung JP (Eds.), The Vitamins, Fundamental Aspects in Nutrition and Health, 5th ed. London: Academic Press, 2017; 161–206.
  2. Holick MF. Vitamin D: Photobiology, metabolism, mechanism of action, and clinical application. In: Favus MJ (Ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 3rd Edition. Philadelphia: Lippincott-Raven, 1996; 74–81.
  3. Lehmann B, MeurerM.Vitamin D metabolism.DermatolTher 2010; 23: 2–12.
  4. Kamao M, Tatematsu S, Hatakeyama S, et al. C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. J Biol Chem 2004; 279: 15897–15907.
  5. Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch BiochemBiophys 2012; 523: 9–18.
  6. Dusso AS, Brown AJ, Slatopolsky E.Vitamin D.Am J Physiol Renal Physiol 2005; 289: F8–28.
  7. Norman AW, Okamura WH, Hammond MW, et al. Comparison of 6-s-cis- and 6-s-trans-locked analogs of 1alpha,25-dihydroxyvitamin D3 indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-scis-nor 6-s-trans-locked analogs are preferred for genomic biological responses. Mol Endocrinol 1997; 11: 1518–1531.
  8. Gil Á, Plaza-Diaz J, Mesa MD.Vitamin D: Classic and Novel Actions.Ann NutrMetab 2018; 72: 87–95.
  9. Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 2016; 96: 365–408.
  10. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96: 252–261.
  11. Ma Y, Johnson CS, Trump DL. Mechanistic insights of vitamin D anticancer effects. VitamHorm 2016; 100: 395–431.
  12. Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007; 179: 1634–1647.
  13. Bikle D.Nonclassic actions of vitamin D.J ClinEndocrinolMetab 2009; 94: 26–34.
  14. BoonstraA, Barrat FJ, Crain C, et al. 1α,25-Dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974–4980.
  15. Penna G, AdoriniL. 1α,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405–2411.
  16. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005; 19: 1067–1077.
  17. Kitson MT, Roberts SK.D-livering the message: the importance of vitamin D status in chronic liver disease.J Hepatol 2012; 57: 897–909.
  18. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010; 55: 2624–2628.
  19. Reese PP, Bloom RD, Feldman HI, et al.Changes in vitamin D binding protein and vitamin D concentrations associated with liver transplantation.Liver Int 2012; 32: 287–296.
  20. Malham M, Jørgensen SP, Ott P, et al. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than Aetiology. World J Gastroenterol 2011; 17: 922–925.
  21. Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. ClinGastroenterolHepatol 2007; 5: 513–520.
  22. Stokes CS, Volmer DA, Grünhage F, et al.Vitamin D in chronic liver disease.Liver Int 2013; 33: 338–352.
  23. BlachS, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet GastroenterolHepatol 2017; 2: 161–176.
  24. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev GastroenterolHepatol 2013; 10: 553–562.
  25. Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 887–893.
  26. Gal-TanamyM, Bachmetov L, Ravid A, et al. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011; 54: 1570–1579.
  27. BitettoD, Fattovich G, Fabris C, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53: 1118–1126.
  28. Terrier B, Carrat F, Geri G, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV–HCV co-infected patients with chronic hepatitis. J Hepatol 2011; 55: 756–761.
  29. Baur K, Mertens JC, Schmitt J, et al.Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients.Liver Int 2012; 32: 635–643.
  30. Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin 2018; 68: 394–424.
  31. Tang A, Hallouch O, Chernyak V, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. AbdomRadiol 2018; 43: 13–25.
  32. Flanagan JN, Zheng S, Chiang KC, et al. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res 2009; 29: 3547–3553.
  33. PourgholamiMH, Akhter J, Lu Y, et al. In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. Cancer Lett 2000; 151: 97–102.
  34. Caputo A, Pourgholami MH, Akhter J, et al. 1,25-Dihydroxyvitamin D3 induced cell cycle arrest in the human primary liver cancer cell line HepG2. Hepatol. Res 2003; 26: 34–39.
  35. Chiang KC, Yeh CN, Chen MF, et al.Hepatocellular carcinoma and vitamin D: a review.J GastroenterolHepatol 2011; 26: 1597–1603.
  36. Bandera-Merchan B, Morcillo S, Martin-Nuñez G, et al. The role of vitamin D and VDR in carcinogenesis: Through epidemiology and basic sciences. J Steroid BiochemMolBiol 2017; 167: 203–218.
  37. VuoloL, Di Somma C, Faggiano A, et al.Vitamin D and cancer.Front Endocrinol 2012; 3: 58.
 

 

Statistics
Article View: 243
PDF Download: 310